Impact of primary platinum-free interval and BRCA1/2 mutation status on treatment and survival in patients with recurrent ovarian cancer

2017 ◽  
Vol 146 (1) ◽  
pp. 58-63 ◽  
Author(s):  
Michael A. Bookman ◽  
Jerzy E. Tyczynski ◽  
Janet L. Espirito ◽  
Thomas W. Wilson ◽  
Ancilla W. Fernandes
Keyword(s):  
Ovarian Cancer ◽  
Recurrent Ovarian Cancer ◽  
Mutation Status ◽  
Free Interval

scholarly journals Correction to: BRCA Mutation Status to Personalize Management of Recurrent Ovarian Cancer: A Multicenter Study

2018 ◽  
Vol 25 (S3) ◽  
pp. 996-996
Author(s):  
Claudia Marchetti ◽  
Rossella De Leo ◽  
Angela Musella ◽  
Marco D’Indinosante ◽  
Ettore Capoluongo ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Multicenter Study ◽  
Brca Mutation ◽  
Recurrent Ovarian Cancer ◽  
Mutation Status

Extending the Platinum-Free Interval with a Non-Platinum Therapy in Platinum-Sensitive Recurrent Ovarian Cancer

Oncology ◽  
2006 ◽  
Vol 71 (5-6) ◽  
pp. 320-326 ◽  
Author(s):  
Sandro Pignata ◽  
Gabriella Ferrandina ◽  
Giovanna Scarfone ◽  
Paolo Scollo ◽  
Franco Odicino ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Recurrent Ovarian Cancer ◽  
Platinum Sensitive ◽  
Free Interval

scholarly journals Prognostic factors modifying the treatment-free interval in recurrent ovarian cancer

2015 ◽  
Vol 139 (2) ◽  
pp. 228-235 ◽  
Author(s):  
Kevin H. Eng ◽  
Bret M. Hanlon ◽  
William H. Bradley ◽  
J. Brian Szender
Keyword(s):  
Ovarian Cancer ◽  
Prognostic Factors ◽  
Recurrent Ovarian Cancer ◽  
Free Interval

scholarly journals WHICH PATIENTS WITH OVARIAN CANCER SHOWS THE COMBINATION OF TRABECTEDIN WITH PEGYLATED LIPOSOMAL DOXORUBICIN

2013 ◽  
Vol 68 (11) ◽  
pp. 115-121 ◽  
Author(s):  
S. V. Khokhlova ◽  
M. V. Cherkasova ◽  
N. F. Orel ◽  
S. V. Limareva ◽  
I. Ya. Bazaeva ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Life Expectancy ◽  
Liposomal Doxorubicin ◽  
Pegylated Liposomal Doxorubicin ◽  
Recurrent Ovarian Cancer ◽  
High Rate ◽  
Comparable Efficacy ◽  
Recurrent Algorithm ◽  
Platinum Sensitive ◽  
Free Interval

Given the high rate of recurrence of ovarian cancer, the search for new therapeutic strategies are topical issue. According to various studies the effectiveness of drug treatment relapse depends on the platinum-free interval, increasing in proportion to its duration. If therapy is platinum-resistant recurrent ovarian cancer is a standard approach, the treatment of platinum-sensitive recurrent algorithm is not fully defined. Comparison of platinum and non-platinum combinations revealed the advantage of combined platinum- treatment for patients with platinum-free interval of more than 6 months without an increase in life expectancy. Non-platinum combination of trabectedin with pegylated liposomal doxorubicin has shown comparable efficacy with an advantage in overall survival in patients with platinum-free interval of 6–12 months. A platinum-free interval prolongation by the use of non-platinum mode increases the efficiency of subsequent platinum-based therapy, increasing the life expectancy of patients . Currently under study molecular markers and prognostic factors allowing to define a group of patients who have the greatest benefit from the use trabectedin with pegylated liposomal doxorubicin as second-line chemotherapy. 

Sustained impact of primary platinum-free interval and BRCA1/2 mutation status on survival in patients with ovarian cancer after multiple lines of therapy.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. 5566-5566
Author(s):  
Michael A. Bookman ◽  
Jerzy E. Tyczynski ◽  
Janet L. Espirito ◽  
Thomas Wilson ◽  
Ancilla Fernandes
Keyword(s):  
Ovarian Cancer ◽  
Mutation Status ◽  
Free Interval

Management of recurrent ovarian cancer: when platinum-based regimens are not a therapeutic option

2019 ◽  
Vol 29 (9) ◽  
pp. 1431-1436 ◽  
Author(s):  
Alice Bergamini ◽  
Luca Bocciolone ◽  
Andrei Fodor ◽  
Massimo Candiani ◽  
Giorgia Mangili
Keyword(s):  
Ovarian Cancer ◽  
Personalized Medicine ◽  
Recurrent Disease ◽  
Therapeutic Option ◽  
Treatment Options ◽  
Treatment Strategies ◽  
Recurrent Ovarian Cancer ◽  
Best Management ◽  
Free Interval ◽  
Treatment Alternatives

Ovarian cancer relapses have been traditionally classified according to the platinum-free interval, leading to an arbitrary categorization of possible scenarios and treatment options. Its relevance in assessing treatment strategies has been revised in the last several years, as the panorama is constantly changing in the era of personalized medicine and targeted therapies. Factors to be considered while defining the best management of recurrent disease, and, consequently, the available treatment alternatives are increasing. Platinum remains one of the milestones of ovarian cancer treatment, but for some patients it might not be an ideal choice for several reasons other than limited platinum sensitivity. This review aims to analyze the scenarios in which platinum is not considered suitable in the management of patients with recurrent ovarian cancer, and the currently available alternatives.

Sign in / Sign up

Export Citation Format

Share Document